Company intelligence / Profile preview

Beta Pharmaceutical

Hangzhou, Zhejiang, Chinabetapharmaceuticals.co.uk ↗

Ownership: Private
Employees: ~2000
Development stage: Other

Overview

Betta Pharmaceuticals has commercialized China's first domestically developed small molecule EGFR inhibitor for NSCLC ("icotinib", Conmana®). It has two NDA-approved programs and over 20 additional clinical-stage assets. Ensartinib is under FDA review for potential US approval as a first-in-class Chinese-developed ALK inhibitor. The pipeline includes both small molecules and biologics targeting major cancers such as NSCLC and metastatic colorectal cancer. The company invests heavily in R&D with robust ongoing development efforts.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Beta Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta Pharmaceutical.

Explore the full profile